NCT06707584Not yet recruiting
Role of MRI in Breast Cancer Subtypes
Role of MRI in Detection of Breast Cancer Molecular Subtypes in Correlation With Immunohistochemistry Results
Source: ClinicalTrials.gov · Last updated 27 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
efficacy of MRI in detection of breast cancer molecular subtypes instead of biopsy and immunohistochemistry
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 25 Nov 2024
- Start date
- 1 Apr 2025
- Primary completion date
- 10 Aug 2029
- Lead sponsor
- Lamiaa Gomaa Ahmed Elsayed
- Diseases
- Childhood cancers
- NCT number
- NCT06707584
What you commit to
- Study type: Observational
- Planned participants: 45
- From 1 Apr 2025 to the primary completion date, 10 Aug 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- breast implants
Other
- general Contraindication of MRI as claustrophobia
Who the study is looking for
- patients with breast cancer confirmed by histopathology,
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.